Key Laboratory of Anesthesiology (Shanghai Jiao Tong University, Ministry of Education), Department of Anesthesiology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Auto-generated profile, based on publicly available information
Wei Xuan
Key Laboratory of Anesthesiology (Shanghai Jiao Tong University, Ministry of Education), Department of Anesthesiology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
Brain perivascular macrophages (PVMs) are attracting increasing attention as this emerging cell population in the brain has multifaced roles in supporting the central nervous system structure, brain development, and maintaining physiological functions. They also widely participate in neurological diseases such as neurodegeneration and ischemic stroke. Moreover, PVMs have been reported to have both beneficial and detrimental effects under different pathological contexts. Advanced research technologies allowed the further in‐depth study of PVMs and revealed novel concepts in their origins, differentiation, and regulatory mechanisms. Deepened understanding of the roles of PVMs in different brain pathological conditions can reveal novel phenotypic changes and regulatory signaling, which might pave the way for the development of novel treatment strategies targeting PVMs.
Introduction: The value of gastric intramucosal pH (pHi) can be calculated from the tonometrically measured partial pressure of carbon dioxide ( $$ {P}_{C{O}_2} $$ ) in the stomach and the arterial bicarbonate content. Low pHi and increase of the difference between gastric mucosal and arterial $$ {P}_{C{O}_2} $$ ( $$ {P}_{C{O}_2} $$ gap) reflect splanchnic hypoperfusion and are good indicators of poor prognosis. Some randomized controlled trials (RCTs) were performed based on the theory that normalizing the low pHi or $$ {P}_{C{O}_2} $$ gap could improve the outcomes of critical care patients. However, the conclusions of these RCTs were divergent. Therefore, we performed a systematic review and meta-analysis to assess the effects of this goal directed therapy on patient outcome in Intensive Care Units (ICUs). Methods: We searched PubMed, EMBASE, the Cochrane Library and ClinicalTrials.gov for randomized controlled trials comparing gastric tonometry guided therapy with control groups. Baseline characteristics of each included RCT were extracted and displayed in a table. We calculated pooled odds ratios (ORs) with 95% confidence intervals (CIs) for dichotomous outcomes. Another measure of effect (risk difference, RD) was used to reassess the effects of gastric tonometry on total mortality. We performed sensitivity analysis for total mortality. Continuous outcomes were presented as standardised mean differences (SMDs) together with 95% CIs. Results: The gastric tonometry guided therapy significantly reduced total mortality (OR, 0.732; 95% CI, 0.536 to 0.999, P = 0.049; I2 = 0%; RD, −0.056; 95% CI, −0.109 to −0.003, P = 0.038; I2 = 0%) when compared with control groups. However, after excluding the patients with normal pHi on admission, the beneficial effects of this therapy did not exist (OR, 0.736; 95% CI 0.506 to 1.071, P = 0.109; I2 = 0%). ICU length of stay, hospital length of stay and days intubated were not significantly improved by this therapy. Conclusions: In critical care patients, gastric tonometry guided therapy can reduce total mortality. Patients with normal pHi on admission contributed to the ultimate result of this outcome; it may indicate that these patients may be more sensitive to this therapy.
20 January 2026 in International Journal of Surgery
Purpose: Aging and metabolic syndrome (MetS) are intertwined risk factors for breast cancer (BC), but the core molecular nexus integrating these states is unknown. This study aimed to identify and validate a causal driver at this intersection. Methods: We integrated transcriptomic datasets from BC, MetS, and aging cohorts to identify common dysregulated genes. Machine learning algorithms prioritized a core diagnostic signature. We used Mendelian randomization to infer causality and characterized the lead candidate using single-cell RNA sequencing and comprehensive preclinical validation. Results: Our analysis identified a 25-gene core at the intersection of BC, MetS, and aging. Machine learning distilled this to five hub genes that formed a highly accurate diagnostic nomogram. Critically, Mendelian randomization established MCRS1 as the sole causal risk factor for BC among these candidates. Single-cell analysis revealed that Mcrs1 is predominantly expressed in proliferating cancer cells, where it drives a transcriptional program of enhanced cell cycle, senescence, and metabolic reprogramming. Accordingly, genetic knockdown of Mcrs1 profoundly suppressed BC cell proliferation and invasion in vitro , and in vivo experiments using an orthotopic BC model in C57BL/6 mice demonstrated significantly reduced tumor growth. Conclusion: This study identifies MCRS1 as a central molecular hub that causally links aging and MetS to BC pathogenesis. MCRS1 is a validated driver of tumor progression and a high-performance biomarker, representing a potential target for therapeutic development, particularly in BC patients with metabolic comorbidities.